ArticleClinical and experimental medicine2025
Prognostic and therapeutic potential of copper-induced cell death-related lncRNAs in lung squamous cell carcinoma.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cuproptosis and prostate cancer: from molecular mechanisms and microenvironment remodeling to precision therapy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Lung squamous cell carcinoma (LUSC), a major subtype of non-small cell lung cancer, remains challenging to treat due to poor prognosis and limited therapeutic options. This study investigates the prognostic and therapeutic implications of copper-induced cell death-related long non-coding RNAs (lncRNAs) in LUSC using data from The Cancer Genome Atlas. Five lncRNAs (AC010328.1, LINC01740, AL358613.2, MIR3945HG, AC002467.1) were identified as independent prognostic markers and incorporated into a risk score model to stratify patients into high- and low-risk groups. Survival analyses revealed significant differences in overall survival, with the high-risk group exhibiting higher immune evasion potential and poorer response to immunotherapy. Functional enrichment analyses highlighted the involvement of these lncRNAs in drug metabolism and tumor biology. Furthermore, tumor mutation burden analysis and immune dysfunction evaluation confirmed the clinical relevance of the model, identifying high-risk patients as more sensitive to targeted drugs such as Quizartinib and Dasatinib. A Nomogram integrating lncRNA risk scores and clinical factors demonstrated robust predictive accuracy for 1-, 3-, and 5-year survival outcomes. This study provides novel biomarkers and actionable insights for improving prognostic assessment and personalizing immunotherapy strategies for LUSC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.